TN2014000152A1 - Sustained-release preparation - Google Patents
Sustained-release preparationInfo
- Publication number
- TN2014000152A1 TN2014000152A1 TNP2014000152A TN2014000152A TN2014000152A1 TN 2014000152 A1 TN2014000152 A1 TN 2014000152A1 TN P2014000152 A TNP2014000152 A TN P2014000152A TN 2014000152 A TN2014000152 A TN 2014000152A TN 2014000152 A1 TN2014000152 A1 TN 2014000152A1
- Authority
- TN
- Tunisia
- Prior art keywords
- sustained
- release preparation
- pioglitazone
- salt
- average
- Prior art date
Links
- 239000003405 delayed action preparation Substances 0.000 title abstract 3
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 6
- 229960005095 pioglitazone Drugs 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000007922 dissolution test Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000012085 test solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011232302 | 2011-10-21 | ||
| PCT/JP2012/077662 WO2013058409A1 (en) | 2011-10-21 | 2012-10-19 | Sustained-release preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2014000152A1 true TN2014000152A1 (en) | 2015-09-30 |
Family
ID=47178262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2014000152A TN2014000152A1 (en) | 2011-10-21 | 2014-04-11 | Sustained-release preparation |
Country Status (30)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6093762B2 (ja) | 2011-10-21 | 2017-03-08 | 武田薬品工業株式会社 | 徐放性製剤 |
| PE20141558A1 (es) | 2012-04-20 | 2014-11-06 | Gilead Sciences Inc | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih |
| US20150141517A1 (en) | 2013-11-15 | 2015-05-21 | Shin-Etsu Chemical Co., Ltd. | Granulated composite, rapid release tablet and method for producing same |
| KR102485766B1 (ko) | 2019-12-11 | 2023-01-09 | 한국유나이티드제약 주식회사 | 생체이용률이 향상된 피오글리타존 함유 약학조성물 |
| UY39094A (es) * | 2020-02-27 | 2021-07-30 | Hk Inno N Corp | Composición farmacéutica que comprende compuesto derivado de bencimidazol |
| JP2023066053A (ja) * | 2021-10-28 | 2023-05-15 | 東和薬品株式会社 | 放出制御医薬組成物 |
| WO2025064867A1 (en) * | 2023-09-21 | 2025-03-27 | Yuva Biosciences, Inc. | Delivery system for mitochondrial health enhancers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810502A (en) | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
| US4820522A (en) | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| JPH0624991A (ja) | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | ウルソデスオキシコール酸持続性製剤 |
| JPH0624959A (ja) | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
| ES2179829T3 (es) | 1992-09-18 | 2003-02-01 | Yamanouchi Pharma Co Ltd | Preparacion de hidrogel de liberacion prolongada. |
| JPH06316517A (ja) | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | 放出制御製剤 |
| WO1998056359A2 (de) | 1997-06-13 | 1998-12-17 | Roland Bodmeier | Zusammensetzungen, die die wirkstofffreisetzung verzögern |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| WO2003013609A1 (fr) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Medicaments a liberation continue |
| US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| KR20050053677A (ko) | 2002-09-20 | 2005-06-08 | 안드렉스 랩스 엘엘씨 | 비구아나이드와 티아졸리디네디온 유도체를 함유한 약제학적 투여형태 |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| IN192749B (cg-RX-API-DMAC7.html) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
| US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
| JP4933033B2 (ja) | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
| EP1607088B1 (en) | 2003-03-17 | 2019-02-27 | Takeda Pharmaceutical Company Limited | Controlled release composition |
| ZA200508932B (en) | 2003-06-06 | 2007-03-28 | Takeda Pharmaceutical | Solid pharmaceutical preparation |
| JP2005015477A (ja) | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | 固形製剤 |
| US20060003002A1 (en) | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| EP1738754B1 (en) | 2004-04-14 | 2015-07-15 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
| MX2007002375A (es) | 2004-08-31 | 2007-04-23 | Pfizer Prod Inc | Formas de dosificacion de liberacion controlada combinando liberacion inmediata y liberacion sostenida de un farmaco de baja solubilidad. |
| CA2623210A1 (en) | 2005-09-22 | 2007-04-05 | Sb Pharmco Puerto Rico Inc. | Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients |
| WO2007054976A2 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
| TWI384985B (zh) | 2005-12-22 | 2013-02-11 | Takeda Pharmaceutical | 固體製劑 |
| CN101410103B (zh) | 2006-03-30 | 2013-04-10 | 日本脏器制药株式会社 | 固体药物制剂 |
| WO2007126135A1 (en) | 2006-04-27 | 2007-11-08 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition of angiotensin ii antagonists with pioglitazone hcl |
| JP5467870B2 (ja) | 2007-02-09 | 2014-04-09 | アルファファーム ピーティーワイ リミテッド | 異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態 |
| TW200914006A (en) * | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
| CN101269040A (zh) * | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | 盐酸吡格列酮缓释滴丸及其制备方法 |
| US8445190B2 (en) | 2008-09-30 | 2013-05-21 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
| TWI478712B (zh) * | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| WO2011049309A2 (ko) | 2009-10-09 | 2011-04-28 | 영진약품공업 주식회사 | 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
| JP2011232302A (ja) | 2010-04-30 | 2011-11-17 | Ricoh Elemex Corp | 画像検査方法及び画像検査装置 |
| CN101884627B (zh) | 2010-07-07 | 2012-01-25 | 青岛黄海制药有限责任公司 | 盐酸吡格列酮胃内滞留缓释片及其制备方法 |
| EP2665479B1 (en) | 2011-01-10 | 2019-06-26 | Zinfandel Pharmaceuticals, Inc. | Methods and drug products for treating alzheimer's disease |
| JP6093762B2 (ja) | 2011-10-21 | 2017-03-08 | 武田薬品工業株式会社 | 徐放性製剤 |
| KR20160056691A (ko) | 2014-11-12 | 2016-05-20 | 삼성에스디아이 주식회사 | 이차전지 |
-
2012
- 2012-10-19 JP JP2014518853A patent/JP6093762B2/ja not_active Expired - Fee Related
- 2012-10-19 US US14/352,785 patent/US9907789B2/en active Active
- 2012-10-19 AR ARP120103908A patent/AR088398A1/es unknown
- 2012-10-19 NZ NZ624275A patent/NZ624275A/en not_active IP Right Cessation
- 2012-10-19 IN IN3169DEN2014 patent/IN2014DN03169A/en unknown
- 2012-10-19 KR KR1020147010504A patent/KR20140081826A/ko not_active Ceased
- 2012-10-19 PH PH1/2014/500856A patent/PH12014500856A1/en unknown
- 2012-10-19 SG SG10201700121YA patent/SG10201700121YA/en unknown
- 2012-10-19 CA CA2852417A patent/CA2852417A1/en not_active Abandoned
- 2012-10-19 WO PCT/JP2012/077662 patent/WO2013058409A1/en not_active Ceased
- 2012-10-19 AP AP2014007645A patent/AP2014007645A0/xx unknown
- 2012-10-19 MX MX2014004679A patent/MX2014004679A/es unknown
- 2012-10-19 PE PE2014000558A patent/PE20141189A1/es not_active Application Discontinuation
- 2012-10-19 UA UAA201405332A patent/UA113858C2/uk unknown
- 2012-10-19 EA EA201490840A patent/EA201490840A1/ru unknown
- 2012-10-19 TW TW101138592A patent/TW201323018A/zh unknown
- 2012-10-19 BR BR112014008744A patent/BR112014008744A2/pt not_active IP Right Cessation
- 2012-10-19 UY UY0001034403A patent/UY34403A/es not_active Application Discontinuation
- 2012-10-19 EP EP12784752.3A patent/EP2768487B1/en active Active
- 2012-10-19 SG SG2014012025A patent/SG2014012025A/en unknown
- 2012-10-19 AU AU2012326976A patent/AU2012326976B2/en not_active Ceased
- 2012-10-19 CN CN201280062591.4A patent/CN104039313A/zh active Pending
-
2014
- 2014-04-11 TN TNP2014000152A patent/TN2014000152A1/en unknown
- 2014-04-13 IL IL232114A patent/IL232114A0/en unknown
- 2014-04-15 DO DO2014000077A patent/DOP2014000077A/es unknown
- 2014-04-17 CL CL2014000992A patent/CL2014000992A1/es unknown
- 2014-04-29 EC ECSP14013328 patent/ECSP14013328A/es unknown
- 2014-04-29 ZA ZA2014/03103A patent/ZA201403103B/en unknown
- 2014-05-09 CR CR20140213A patent/CR20140213A/es unknown
- 2014-05-14 CO CO14103846A patent/CO6960544A2/es unknown
- 2014-05-15 MA MA37034A patent/MA35717B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000152A1 (en) | Sustained-release preparation | |
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| NZ602685A (en) | Concentrated protein formulations and uses thereof | |
| PH12013500223A1 (en) | Oral care product and methods of use and manufacture thereof | |
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
| PH12016501175A1 (en) | Formulations of deoxycholic acid and salts thereof | |
| ZA202210899B (en) | Solutons for increasing the stability and shelf life of an organ and tissue preservation solution | |
| EA201690079A1 (ru) | Композиция, содержащая глутаминовую-n,n-диуксусную кислоту (glda), воду и фермент | |
| ZA201504284B (en) | Solution for preserving vascular conduits | |
| PH12017501397B1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| TR201001417A1 (tr) | Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu | |
| MX370065B (es) | Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico. | |
| AU2018258588A8 (en) | Inhibitors of TRIM33 and methods of use | |
| EA201401200A1 (ru) | Новая композиция альфентанила для лечения острой боли | |
| WO2012074237A3 (ko) | 도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물 | |
| EA201390844A1 (ru) | Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения | |
| MY163015A (en) | Dentifrice composition | |
| UA110933C2 (uk) | Композиція для лікування есенціальної тромбоцитемії | |
| TN2010000012A1 (en) | Stable pharmaceutical composition of a water soluble vinorelbine salt | |
| RU2010129784A (ru) | Способ приготовления противотуберкулезного лекарственного препарата | |
| TR201009399A2 (tr) | Hızlı çözünen efervesan rosuvastatin formülasyonları. | |
| MX2009009830A (es) | Composiciones farmaceuticas estables y metodos de fabricacion y uso de las mismas. | |
| MX2023013066A (es) | Formulaciones de etelcalcetida. | |
| TH156810A (th) | สารเตรียมชนิดปลดปล่อยแบบทยอย | |
| WO2012036529A3 (en) | (s)-n,n-dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine derivatives, pharmaceutical compositions containing the derivatives and manufacturing methods thereof |